Key Takeaways Eli Lilly's Omvoh, Ebglyss, Kisunla and Jaypirca added over $540M in revenues in H1 2025.These drugs are under study for new uses, with approvals expected to expand market reach.The Zacks Consensus Estimate for LLY's 2025 EPS rose to $22.97, while the same for 2026 increased to $30.95.Eli Lilly and Company (LLY) has gained tremendous market value in the past 2-3 years due to the success of its popular GLP-1 drugs, Mounjaro for type II diabetes and Zepbound for obesity.However, Lilly has gained ...